Liposome technology for drug delivery against mycobacterial infections

Current Pharmaceutical Design

Volumn 10, Issue 26, 2004, Pages 3263-3274

  Khuller, G K ^a   Kapur, Manisha ^b   Sharma, Sadhna ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b INSTITUTE OF MICROBIAL TECHNOLOGY   (India)

Author keywords

Chemotherapy; Drug delivery; Liposomes; Mycobacterium avium; Mycobacterium tuberculosis; Tuberculosis

Indexed keywords

1 CYCLOPROPYL 7 [3 [(ETHYLAMINO)METHYL] 1 PYRROLIDINYL] 6,8 DIFLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; AMIKACIN; ASIATICOSIDE; AZITHROMYCIN; CAPREOMYCIN; CERULENIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; GENTAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; LIPOSOME; MACROGOL; PHOSPHATIDYLETHANOLAMINE; RESORCINOMYCIN A; RIFABUTIN; RIFAMPICIN; SPARFLOXACIN; STREPTOMYCIN;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; BIOCOMPATIBILITY; BIODEGRADABILITY; BIOTECHNOLOGY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; SUSTAINED RELEASE FORMULATION;

ANIMALS; ANTITUBERCULAR AGENTS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; HUMANS; INDIA; LIPOSOMES; MYCOBACTERIUM INFECTIONS;

EID: 4644227792     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383250     Document Type: Review

References (87)

1. Bangham AD. Membrane models with phospholipids. Prog Biophys Mol Biol 1968; 18: 29-95.
2. Lasic DD. Liposomes: from physics to applications. Amsterdam, Elsevier: 1993; 9-42.
3. Lasic DD. Novel applications of liposomes. Tibtech 1998; 16: 307-21.
4. Lasic DD, Needham D. The stealth liposomes: a prototypical biomaterial. Chem Rev 1995; 95: 2601-28.
5. Duzgunes N. In: Lasic DD, Papahadjopoulos D Ed, Medical application of liposomes. Elsevier 1998; 189-219.
6. Barnstein ZP, Chanan-Khan A, Miller KC, Northfelt DW, Lopez-Berestein G, Gill PS. A multicentre phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Cancer 2002; 95: 2555-61.
7. Kotwani RN, Bodhe PV, Kirodian BG, Mehta KP, Ali US, Kshirsagar NA. Treatment of neonatal candidiasis with liposomal amphotericin B (L-AMB-LRC-1): phase II study. Indian Pediat 2003; 40: 545-50.
8. Bloom BR, Murray CJL. Tuberculosis: commentary on a re-emergent killer. Science 1992; 257: 1055-64.
9. Barnes P, Blotch AB, Davidson BT, Snyder Jr DEN. Tuberculosis in patients with immunodeficiency virus infection. N Eng J Med 1991; 324: 1644-50.
10. Isseman MD. Treatment and implications of multidrug resistant tuberculosis for the 21st century. Chemotherapy 1999; 45: 34-40.
11. Fine P. Leprosy and tuberculosis - an epidemiological comparison. Tubercle 1984; 65: 137-53.
12. Barksdale L, Kim KS. Mycobacterium. Bacteriol Rev 1977; 41: 217-372.
13. Maruyama K. PEG-immunoliposome. Biosci Rep 2002; 22: 251-66.
14. Li Hong, Song JH, Park JS, Han K. Polyethylene glycol-coated liposomes for oral delivery of recombinant human epidermal growth factor. Int J Pharm 2003; 258: 11-9.
15. Grants SA. The holy grail: long acting local anaesthetics and liposomes. Best Pract Res Clin Anaesthesiol 2002; 16: 345-52.
16. Orozco LC, Quintana FO, Beltran RM, Moren L, Wasserman M, Rodriguez G. The use of rifampicin and isoniazid entrapped in liposomes for the treatment of murine tuberculosis. Tubercle 1986; 67: 91-7.
17. 3H-dihydrostreptomycin in solution and liposomal form in normal and M. tuberculosis infected mice. Biomed Pharmacother 1986; 40: 416-20.
18. Vladimirskii MA, Ladygina GA, Tentosova AI. Effectiveness of liposome-incorporated streptomycin in experimental tuberculosis in mice. Antibiotiki 1983; 28: 23-6.
19. Ehlers S, Bucke W, Leitzke S, Fortmann L, Smith D, Hansch H, et al. Liposomal amikacin for treatment of M. avium infections in clinically relevant experimental settings. Zentralbl Bakteriol 1996; 284: 218-31.
20. Klemens SP, Cynamon MH, Swenson CE, Ginsberg RS. Liposome encapsulated gentamycin therapy of M. avium complex infection in beige mice. Antimicrob Agents Chemother 1990; 34: 967-70.
21. Tomioka H, Saito H, Sato K, Yoneyama T. Therapeutic efficacy of liposome encapsulated kanamycin against Mycobacterium intracellulare infection induced in mice. Am Rev Resp Dis 1991; 145: 575-9.
22. Deol P, Khuller GK. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta 1997; 1334: 161-72.
23. Das AR, Dattagupta N, Sridhar CN, Wu W. A novel thiocationic liposomal formulation of antisense oligonucleotides with activity against Mycobacterium tuberculosis. Scand J Infect Dis 2003; 35: 168-74.
24. Adams LB, Sinha I, Franzblau SG, Krahembuhl JL, Mehta RT. Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. Antimicrob Agents Chemother 1999; 43: 1638-43.
25. Kansal RG, Gomez-Flores R, Sinha I, Mehta RT. Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection. Antimicrob Agents Chemother 1997; 41: 17-23.
26. Gangadharam PRJ, Ashtekar DA, Ghori N, Goldstein JA, Debs RJ, Duzgunes N. Chemotherapeutic potential of free and liposome encapsulated streptomycin against experimental Mycobacterium avium infections in beige mice. J Antimicrob Chemother 1991; 28: 425-35.
27. Duzgunes N, Ashtekar DR, Flasher DL, Ghori N, Debs RJ, Friend DS, et al. Treatment of Mycobacterium avium - M. intracellulare complex infection in beige mice with free and liposome-encapsulated streptomycin - role of liposome type and duration of treatment. J Infect Dis 1991; 164: 143-51.
28. Gaspar MM, Neves S, Portaels F, Pedrosa J, Silva MT, Cruz MEM. Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infection. Antimicrob Agents Chemother 2000; 44: 2424-30.
29. Onyeji CO, Nightingale CH, Nicolau DP, Quintiliani R. Efficacy of liposome encapsulated clarithromycin and ofloxacin against Mycobacterium avium - Mycobacterium intracellulare complex in human macrophages. Antimicrob Agents Chemother 1994; 38: 523-7.
30. Saito H, Tomioka H. Therapeutic efficacy of liposome entrapped rifampin against Mycobacterium avium complex infection in mice. Antimicrob Agents Chemother 1989; 33: 429-33.
31. Mehta RT, Keyhani A, McQueen TJ, Rosenbaum B, Rolston KV, Tarrand JJ. In vitro activities of free and liposomal drugs against Mycobacterium avium - Mycobacterium intracellulare complex and Mycobacterium tuberculosis. Antimicrob Agents Chemother 1993; 37: 2584-7.
32. Petersen EA, Grayson JB, Hersh EM, Dorr RT, Chiang SM, Oka M, Proffit RT. Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in beige mouse model. J Antimicrob Chemother 1996; 38: 819-28.
33. Kesavalu L, Goldstein JA, Debs RJ, Duzgunes N, Gangadharam PRJ. Differential effects of free and liposome encapsulated amikacin on the survival of Mycobacterium avium complex in mouse peritoneal macrophages. Tubercle 1990; 71: 215-7.
34. Leitzke S, Bucke W, Borner K, Miiller R, Hahn H, Ehlers S. Rationale for and efficacy of prolonged interval treatment using liposome encapsulated amikacin in experimental Mycobacterium avium infection. Antimicrob Agents Chemother 1998; 42: 459-61.
35. Wasserman M, Beltran RM, Quintana FO, Mendoza PM, Orozco LC, Rodriguez G. A simple technique for the entrapment of rifampicin and isoniazid into liposomes. Tubercle 1986; 67: 83-90.
36. Agarwal A, Kandpal H, Gupta HP, Singh NB, Gupta CM. Tuftsin-bearing liposomes as rifampicin vehicles in treatment of tuberculosis in mice. Antimicrob Agents Chemother 1994; 38: 588-93.
37. Deol P, Khuller GK, Joshi K. Therapeutic efficacies of isoniazid and rifampicin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother 1997; 41: 1211-4.
38. Labana S, Pandey R, Sharma S, Khuller GK. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Intl J Antimicrob Agents 2002; 20: 301-14.
39. Suarez S, O'Hara P, Kozantseva M, Newcaner CE, Hopfer R, McMurray DN, Mickey AJ. Airway delivery of rifampicin in microparticles for the treatment of tuberculosis. J Antimicrob Chemother 2000; 48: 431-4.
40. O'Brien RJ, Lyle MA, Snier DE Jr. Rifabutin (ansamycin LM 427) : a new rifamycin-5 derivative for the treatment of mycobacterial disease. Rev Infect Dis 1987; 9: 519-30.
41. Gangadharam PR, Perumal VK, Podapati NR, Kesavalu L, Iseman MD. In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium infections in beige mice. Antimicrob Agents Chemother 1988; 32: 1400-03.
42. Shimitzu T, Yashida U, Ukuyama T. Effect of amikacin on experimenal tuberculosis of mice. Kekkaku 1979; 43-9.
43. Schiffelers R, Storm G, Bakkerwoundenberg I. Liposome encapsulated aminoglycosides in pre-clinical and clinical studies. J Antimicrob Chemother 2001; 48: 333-44.
44. Fielding RM, Mukwaya G, Sandhaus RA. In: Woodle MC, Storm G Eds, Long circulating liposomes: Old drugs, new therapeutics. Austin Tx, Springer-Verlag and Landes Bioscience. 1998; 213-26.
45. Fielding RM, Moon-McDermott L, Levis RO. Biodistribution of a small unilamellar low clearance liposomal amikacin formulation after extravascular administration. J Drug Targeting 1999; 6: 415-26.
46. Fielding RM, Moon-McDermott L, Lewis RO, Harner MJ. Pharmacokinetics and urinary excretion of amikacin in low clearance unilamellar liposomes after a single or repeated intravenous administration in the rhesus monkey. Antimicrob Agents Chemother 1999; 43: 503-9.
47. Dhillon J, Fielding R, Adler-Moorl J, Goodall RL, Mitchison O. The activity of low-clearance liposomal amikacin in experimental murine tuberculosis. J Antimicrob Chemother 2001; 48: 869-76.
48. Donald PR, Sirgel FA, Venter A, Smit E, Parkin DP, Van de wal BW, Mitchison DA. The early bactericidal activity of a low-clearance liposomal amikacin in pulmonary tuberculosis. J Antimicrob Chemother 2001; 48: 877-80.
49. Bermudez LE, Yau-Young AO, Palmer GS, Ginsberg RS. Treatment of disseminated Mycobacterium avium complex infection in beige mice with liposome-encapsulated aminoglycosides. J Infect Dis 1990; 161: 1262-8.
50. Whitehead TC, Loveirng AM, Cropley IM, Wade P, Davidson RN. Kinetics and toxicity of liposomal and conventional amikacin in a patient with multi drug resistant tuberculosis. Eur J Clin Microbiol Infect Dis 1998; 17: 794-7.
51. Wichert BV, Gonzalez-Rothi RJ, Straub LE, Wichert BM, Schieier H. Amikacin liposomes: characterization, aerosolization and in vitro activity against Mycobacterium avium intracellulare in alveolar macrophages. Intl J Pharm 1992; 78: 227-35.
52. Barry VC, Belton JG, Conalty ML, Denneny JM, Edward DW, O'Sullivan JF, et al. A new series of phenazines (riminocompounds) with high antituberculosis activity. Nature 1957; 179: 1013-5.
53. Levy L, Shephard CC, Fasal P. Clofazimine therapy of lepromatous leprosy caused by dapsone-resistant Mycobacterium leprae. Am J Trop Med Hyg 1972; 21: 315-21.
54. Agins BD, Beriman DS, Spicehandler D, El-Sadr W, Simberkoff MS, Rahal JJ. Effect of combined therapy with ansamycin, clofazimine, ethambutol and isoniazid for Mycobacterium avium infection in patients with AIDS. J Infect Dis 1989; 159: 784-7.
55. Garrelts JC. Clofazimine: a review of its uses in leprosy and Mycobacterium avium complex infection. DICP-Ann Pharmacother 1991; 25: 525-31.
56. Mehta RT. Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium - M. intracellulare complex infection. Antimicrob Agents Chemother 1996; 40: 1893-902.
57. Peters K, Leitzke S, Diederichs JE, Barner K, Hahn H, Muller RH, Ehlers S. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother 2000; 45: 77-83.
58. Morgan JR, Williams KE. Preparation and properties of liposome-associated gentamycin. Antimicrob Agents Chemother 1980; 17: 544-8.
59. Nightingale SD, Saletan SL, Swenson CE, Lawrence AJ, Watson DA, Pilkiewicz FG, Silverman EG, Cal SX. Liposome encapsulated gentamycin treatment of Mycobacterium avium-Mycobacterium intracellulare complex bacteremia in AIDS patients. Antimicrob Agents Chemother 1993; 37: 1869-72.
60. Vladimirsky MA, Ladygina GA. Antibacterial activity of liposome-entrapped streptomycin in mice infected with M. tuberculosis. Biomed Pharmacother 1982; 36: 375-7.
61. Majumdar S, Flasher D, Friend DS, Nassos P, Yajko D, Hadley WK, Duzgunes N. Efficacies of liposome encapsulated streptomycin and ciprofloxacin against Mycobacterium avium - M. intracellulare complex infections in human peripheral blood monocyte/macrophages. Antimicrob Agents Chemother 1992; 36: 2805-15.
62. Gangadharam PRJ, Ashtekar DR, Flasher DL, Duzgunes N. Therapy of Mycobacterium avium complex infections in beige mice with streptomycin encapsulated in sterically stabilized liposomes. Antimicrob Agents Chemother 1995; 39: 725-30.
63. Duzgunes N, Flasher D, Venkata Reddy M, Luna-Herrera J, Gangadharam PRJ. Treatment of intracellular M. avium complex infection by free and liposome encapsulated sparfloxacin. Antimicrob Agents Chemother 1996; 40: 2618-21.
64. LeConte P, Gallou FL, Potel G, Struillou L, Baron O, Drugeon HB. Pharmacokinetics, toxicity and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model. Antimicrob Agents Chemother 1994; 38: 2695-701.
65. Gomez-Flores R, Hsia R, Tomez-Guerra R, Mehta RT. Enhanced intramacrophage activity of resorcinomycin A against Mycobacterium avium - Mycobacterium intracellulare complex after liposome encapsulation. Antimicrob Agents Chemother 1996; 40: 2545-9.
66. Oh Y, Nix DE, Straubinger RM. Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. Antimicrob Agents Chemother 1995; 39: 2104-11.
67. Duzgunes N, Perumal VK, Kesavalu L, Goldstein JA, Debs RJ, Gangadharam PRJ. Enhanced effect of liposome encapsulated amikacin on Mycobacterium avium - Mycobacterium intracellulare complex infection in beige mice. Antimicrob Agents Chemother 1988; 32: 1404-11.
68. Cynamon MH, Swenson CE, Palmer GS, Ginsberg RS. Liposome encapsulated-amikacin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 1989; 33: 1179-83.
69. Onyeji CO, Nightingale CH, Tessier PR, Nicolau DP, Bow LM. Activities of clarithromycin, azithromycin and ofloxacin in combination with liposomal or unencapsulated granuloycyte-macrophage colony stimulating factor against intramacrophage Mycobacterium avium - Mycobacterium intracellulare. J Infect Dis 1995; 172: 810-16.
70. Bermudez LE, Wu M, Young LS. Intracellular killing of Mycobacterium avium complex by rifapentine and liposome encapsulated amikacin. J Infect Dis 1987; 156: 510-13.
71. Vladimirsky VA, Ladygina GA. Antibacterial activity of liposome entrapped streptomycin in mice infected with Mycobacterium tuberculosis. Biomed Pharmacother 1982; 36: 375-7.
72. Poste G. Liposome targeting in vivo: problems and opportunities. Biol Cell 1983; 47: 19-38.
73. Poste G, Bucana C, Raz A, Bugelski P, Kirsh R, Fidler IJ. Analysis of systemically administered liposomes and implications for their use in drug delivery. Cancer Res 1982; 42: 1412-22.
74. Abra RM, Hunt CA, Lau DT. Liposome disposition in vivo VI: Delivery to the lung. J Pharm Sci 1984; 73: 203-6.
75. Cynamon MH, Klemens SP, Swenson CE. TLC G-65 in combination with other agents in therapy of Mycobacterium avium infection in beige mice. J Antimicrob Chemother 1992; 29: 693-9.
76. Gomez-Flores R, Tucker SD, Kansal R, Tamez-Guerra R, Mehta RT. Enhancement of antibacterial activity of clofazimine against Mycobacterium avium - Mycobacterium intracellulare complex infection induced by IFN-gamma is mediated by TNF-alpha. J Antimicrob Chemother 1997; 39: 189-97.
77. Fielding RM, Levis RO, Moon-McDermott L. Altered tissue distribution and elimination of amikacin encapsulated in unilamellar low clearance liposomes (Mikasome). Pharm Res 1998; 15: 1775-8.
78. Rodrigues C, Gameiro P, Prieto M, de Castro B. Interaction of rifampicin and isoniazid with large unilamellar liposomes: Spectroscopic location studies. Biochim Biophys Acta 2003; 1620: 151-9.
79. Medda S, Das N, Mahato SB, Mahadeva PR, Basu MK. Glycoside-bearing liposomal delivery systems against macrophage-associated disorders involving Mycobacterium leprae and Mycobacterium tuberculosis. Ind J Biochem Biophys 1995; 32: 147-51.
80. Sritharan M. Studies on the tissue distribution of liposome associated clofazimine an antileprosy drug. Methods Find Exp Clin Pharmacol 1993; 15: 107-11.
81. Kurunov IuN, Ursov IG, Krasnov VA, Petrenko TI, Lakovchenoko NN, Svistelnik AV, Filimonov PA. Effectiveness of liposomal antibacterial drugs in the inhalation therapy of experimental tuberculosis. Probl Tuberk 1995; 1: 38-40.
82. Kurunov IuN, Kaledin VI, Popova NA, Panteleeva AG. Effectiveness of a liposomal form of rifampicin in the treatment of experimental tuberculosis in mice. Probl Tuberk 1992; 1: 13-5.
83. Vladimirskii MA, Ladhygina GA, Stepanov VM. Pharmacokinetics of dihydrostreptomycin, after intravenous administration as a liposomal preparation, in the blood serum and tissues of intact mice and those with generalized tuberculosis. Antibiotiki 1984; 29: 181-5.
84. Lasic DD. Recent developments in medical applications of liposomes: sterically stabilized liposomes in cancer therapy and gene delivery in vivo. J Control Rel 1997; 48: 203-22.
85. Danelishvilli L, Bermudez LE. Role of type I cytokines in host defense against Mycobacterium avium infection. Curr Pharm Design 2003; 9(1): 61-5.
86. Maesaki S. Drug delivery system of anti-fungal and parasitic agents. Curr Pharm Design 2002; 8(6): 433-40.
87. Moribe K, Maruyama K. Pharmaceutical design of the liposomal antimicrobial agents for infectious disease. Curr Pharm Design 2002; 8(6): 441-54.